Considerations for defining medication exposure when analyzing real-world data.

Clary, Alecia; Lin, Nancy D; Lasky, Tamar; Reynolds, Matthew W; Chokkalingam, Anand; Rodriguez-Watson, Carla

Clary, Alecia; Lin, Nancy D; Lasky, Tamar; Reynolds, Matthew W; Chokkalingam, Anand; Rodriguez-Watson, Carla.

Afiliação

Clary A; Resesarch, The Reagan-Udall Foundation for the FDA, Washington, District of Columbia, USA.
Lin ND; Global Epidemiology, IQVIA Real World Solutions, Bridgewater, New Jersey, USA.
Lasky T; Office of the Commissioner/Office of Digital Transformation, The United States Food and Drug Administration, Office of Data, Analytics, & Research, Office of the Commissioner, Washington, District of Columbia, USA.
Reynolds MW; Scientific Affairs, IQVIA Real-World Solutions, Washington, District of Columbia, USA.
Chokkalingam A; Real World Evidence, Gilead Sciences, Foster City, California, USA.
Rodriguez-Watson C; Resesarch, The Reagan-Udall Foundation for the FDA, Washington, District of Columbia, USA.

Pharmacoepidemiol Drug Saf ; 32(8): 933-937, 2023 Aug.

Article em En | MEDLINE | ID: mdl-36929112

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Pharmacoepidemiol Drug Saf Assunto da revista: EPIDEMIOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google